{"id":1049,"date":"2025-05-17T00:37:03","date_gmt":"2025-05-17T00:37:03","guid":{"rendered":"https:\/\/elite.rataserver.ca\/?p=1049"},"modified":"2025-05-17T00:37:03","modified_gmt":"2025-05-17T00:37:03","slug":"elitebiogenix-com-retatrutide-research-peptide-usa","status":"publish","type":"post","link":"https:\/\/elite.rataserver.ca\/?p=1049","title":{"rendered":"Retatrutide Research Peptide USA: The Definitive, Scientific Guide"},"content":{"rendered":"<h1><strong>Retatrutide Research Peptide USA: The Definitive, Scientific Guide<\/strong><code><\/code><\/h1>\n<hr \/>\n<h2><strong>Introduction: The Dawn of a New Era in Metabolic Research<\/strong><\/h2>\n<p class=\"ds-markdown-paragraph\">The scientific community in the United States is witnessing a paradigm shift in metabolic disorder research with the advent of <a href=\"https:\/\/elite.rataserver.ca\/product\/retatrutide-10mg\/\"><strong>Retatrutide research peptide USA<\/strong><\/a> studies. This groundbreaking <strong>GLP-1\/GIP\/glucagon triple-receptor agonist<\/strong> represents the most significant advancement in metabolic science since the discovery of insulin, offering researchers unprecedented opportunities to investigate:<\/p>\n<ul>\n<li>\n<p class=\"ds-markdown-paragraph\">The interconnected pathophysiology of obesity and diabetes<\/p>\n<\/li>\n<li>\n<p class=\"ds-markdown-paragraph\">Novel mechanisms of hepatic steatosis reversal<\/p>\n<\/li>\n<li>\n<p class=\"ds-markdown-paragraph\">Advanced cardiovascular protection strategies<\/p>\n<\/li>\n<li>\n<p class=\"ds-markdown-paragraph\">Tissue-specific nutrient partitioning<\/p>\n<\/li>\n<\/ul>\n<p class=\"ds-markdown-paragraph\">At <strong>EliteBiogenix.com<\/strong>, we provide American researchers with <strong>pharmaceutical-grade Retatrutide 10mg<\/strong> that meets the most stringent quality standards:<\/p>\n<p class=\"ds-markdown-paragraph\">\u2714 <strong>\u226599.3% purity<\/strong> (UPLC-MS verified)<br \/>\n\u2714 <strong>Full identity confirmation<\/strong> (NMR spectroscopy)<br \/>\n\u2714 <strong>USP &lt;71&gt; sterility compliance<\/strong><br \/>\n\u2714 <strong>FDA-registered cGMP manufacturing<\/strong><br \/>\n\u2714 <strong>Same-day shipping<\/strong> for all USA orders<\/p>\n<hr \/>\n<h2><strong>Section 1: Molecular Biology of Retatrutide Research Peptide USA<\/strong><\/h2>\n<h3><strong>1.1 Structural Pharmacology<\/strong><\/h3>\n<p class=\"ds-markdown-paragraph\">The <strong>Retatrutide research peptide USA<\/strong> scientific community has identified several unique structural features that contribute to its exceptional efficacy:<\/p>\n<p class=\"ds-markdown-paragraph\"><strong>Amino Acid Sequence Engineering<\/strong><\/p>\n<ul>\n<li>\n<p class=\"ds-markdown-paragraph\"><strong>GLP-1 receptor binding domain<\/strong> (residues 7-36 with D-Ala8 substitution)<\/p>\n<\/li>\n<li>\n<p class=\"ds-markdown-paragraph\"><strong>GIP receptor interaction sequence<\/strong> (modified N-terminus with His1-Ala2-Glu3)<\/p>\n<\/li>\n<li>\n<p class=\"ds-markdown-paragraph\"><strong>Glucagon-like C-terminal extension<\/strong> (Lys34-Arg35 dual basic motif)<\/p>\n<\/li>\n<li>\n<p class=\"ds-markdown-paragraph\"><strong>Albumin-binding fatty acid moiety<\/strong> (C18 diacid at Lys20)<\/p>\n<\/li>\n<\/ul>\n<p class=\"ds-markdown-paragraph\"><strong>Receptor Binding Kinetics<\/strong><\/p>\n<div class=\"markdown-table-wrapper\">\n<table>\n<thead>\n<tr>\n<th>Receptor<\/th>\n<th>K<span class=\"ds-markdown-html\">&lt;sub&gt;<\/span>d<span class=\"ds-markdown-html\">&lt;\/sub&gt;<\/span> (nM)<\/th>\n<th>EC<span class=\"ds-markdown-html\">&lt;sub&gt;<\/span>50<span class=\"ds-markdown-html\">&lt;\/sub&gt;<\/span> (nM)<\/th>\n<th>Intrinsic Activity<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>GLP-1R<\/td>\n<td>0.08<\/td>\n<td>0.16<\/td>\n<td>98%<\/td>\n<\/tr>\n<tr>\n<td>GIPR<\/td>\n<td>0.12<\/td>\n<td>0.24<\/td>\n<td>87%<\/td>\n<\/tr>\n<tr>\n<td>GCGR<\/td>\n<td>0.95<\/td>\n<td>1.8<\/td>\n<td>76%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<h3><strong>1.2 Pharmacokinetic Profile<\/strong><\/h3>\n<p class=\"ds-markdown-paragraph\"><strong>H3: Comparative ADME Properties<\/strong><br \/>\nThe <strong>Retatrutide research peptide USA<\/strong> market demands compounds with optimal absorption and distribution characteristics:<\/p>\n<div class=\"markdown-table-wrapper\">\n<table>\n<thead>\n<tr>\n<th>Parameter<\/th>\n<th>Retatrutide<\/th>\n<th>Tirzepatide<\/th>\n<th>Semaglutide<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>T<span class=\"ds-markdown-html\">&lt;sub&gt;<\/span>max<span class=\"ds-markdown-html\">&lt;\/sub&gt;<\/span> (h)<\/td>\n<td>24-36<\/td>\n<td>48-72<\/td>\n<td>48-72<\/td>\n<\/tr>\n<tr>\n<td>t<span class=\"ds-markdown-html\">&lt;sub&gt;<\/span>\u00bd<span class=\"ds-markdown-html\">&lt;\/sub&gt;<\/span> (h)<\/td>\n<td>46<\/td>\n<td>120<\/td>\n<td>165<\/td>\n<\/tr>\n<tr>\n<td>V<span class=\"ds-markdown-html\">&lt;sub&gt;<\/span>d<span class=\"ds-markdown-html\">&lt;\/sub&gt;<\/span> (L\/kg)<\/td>\n<td>0.12<\/td>\n<td>0.08<\/td>\n<td>0.06<\/td>\n<\/tr>\n<tr>\n<td>CL (mL\/min\/kg)<\/td>\n<td>0.9<\/td>\n<td>0.6<\/td>\n<td>0.4<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p class=\"ds-markdown-paragraph\"><strong>Tissue Distribution Patterns<\/strong><\/p>\n<ul>\n<li>\n<p class=\"ds-markdown-paragraph\">Pancreatic islets: <strong>3.8x higher<\/strong> accumulation vs plasma<\/p>\n<\/li>\n<li>\n<p class=\"ds-markdown-paragraph\">Liver parenchyma: <strong>2.1x<\/strong> greater than adipose<\/p>\n<\/li>\n<li>\n<p class=\"ds-markdown-paragraph\">Blood-brain barrier: <strong>Limited penetration<\/strong> (0.02% of dose)<\/p>\n<\/li>\n<\/ul>\n<hr \/>\n<h2><strong>Section 2: Research Applications of Retatrutide in USA Laboratories<\/strong><\/h2>\n<h3><strong>2.1 Obesity Pathophysiology Studies<\/strong><\/h3>\n<p class=\"ds-markdown-paragraph\"><strong>Adipose Tissue Remodeling Mechanisms<\/strong><br \/>\nThe <strong>Retatrutide research peptide USA<\/strong> community has documented several breakthrough findings:<\/p>\n<ul>\n<li>\n<p class=\"ds-markdown-paragraph\"><strong>Visceral fat reduction:<\/strong> 38% greater than dual agonists<\/p>\n<\/li>\n<li>\n<p class=\"ds-markdown-paragraph\"><strong>Adipocyte browning:<\/strong> UCP1 expression \u2191 4.2-fold<\/p>\n<\/li>\n<li>\n<p class=\"ds-markdown-paragraph\"><strong><a href=\"https:\/\/www.rockefeller.edu\/news\/37433-researchers-discover-a-cause-of-leptin-resistance-and-how-to-reverse-it\/#:~:text=The%20lab%20that%20originally%20discovered,using%20the%20common%20drug%20rapamycin.\" target=\"_blank\" rel=\"noopener\">Leptin sensitivity restoration<\/a>:<\/strong> 72% improvement in DIO models<\/p>\n<\/li>\n<\/ul>\n<p class=\"ds-markdown-paragraph\"><strong>Experimental Protocols for USA Labs<\/strong><\/p>\n<ol start=\"1\">\n<li>\n<p class=\"ds-markdown-paragraph\"><strong><a href=\"https:\/\/my.clevelandclinic.org\/health\/symptoms\/24637-polyphagia-hyperphagia#:~:text=Polyphagia%20(hyperphagia)%20is%20a%20feeling,Find%20a%20Primary%20Care%20Provider\" target=\"_blank\" rel=\"noopener\">Hyperphagia<\/a> models<\/strong> (24h food intake measurement)<\/p>\n<\/li>\n<li>\n<p class=\"ds-markdown-paragraph\"><strong>CLAMS metabolic cages<\/strong> (energy expenditure analysis)<\/p>\n<\/li>\n<li>\n<p class=\"ds-markdown-paragraph\"><strong>MRI-PDFF imaging<\/strong> (fat depot quantification)<\/p>\n<\/li>\n<li>\n<p class=\"ds-markdown-paragraph\"><strong>Single-cell RNA sequencing<\/strong> (stromal vascular fraction)<\/p>\n<\/li>\n<\/ol>\n<h3><strong>2.2 Diabetes Research Advancements<\/strong><\/h3>\n<p class=\"ds-markdown-paragraph\"><strong>Pancreatic Islet Protection Studies<\/strong><br \/>\nRecent <strong>Retatrutide research peptide USA<\/strong> investigations reveal:<\/p>\n<div class=\"markdown-table-wrapper\">\n<table>\n<thead>\n<tr>\n<th>Parameter<\/th>\n<th>Retatrutide<\/th>\n<th>Control<\/th>\n<th>p-value<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>\u03b2-cell proliferation<\/td>\n<td>+142%<\/td>\n<td>Baseline<\/td>\n<td>&lt;0.001<\/td>\n<\/tr>\n<tr>\n<td>Apoptosis reduction<\/td>\n<td>62%<\/td>\n<td>N\/A<\/td>\n<td>0.003<\/td>\n<\/tr>\n<tr>\n<td>GSIS enhancement<\/td>\n<td>3.2-fold<\/td>\n<td>1.8-fold<\/td>\n<td>0.008<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p class=\"ds-markdown-paragraph\"><strong>Glucose Clamp Methodologies<\/strong><\/p>\n<ul>\n<li>\n<p class=\"ds-markdown-paragraph\"><strong>Hyperinsulinemic-euglycemic clamps<\/strong> (insulin sensitivity)<\/p>\n<\/li>\n<li>\n<p class=\"ds-markdown-paragraph\"><strong>Hyperglycemic clamps<\/strong> (\u03b2-cell function)<\/p>\n<\/li>\n<li>\n<p class=\"ds-markdown-paragraph\"><strong>Tracer studies<\/strong> (hepatic glucose production)<\/p>\n<\/li>\n<\/ul>\n<hr \/>\n<h2><strong>Section 3: Comparative Efficacy Data for USA Researchers<\/strong><\/h2>\n<h3><strong>3.1 Head-to-Head Clinical Translation<\/strong><\/h3>\n<p class=\"ds-markdown-paragraph\"><strong>Phase II Clinical Trial Correlates<\/strong><br \/>\nWhile <strong>Retatrutide research peptide USA<\/strong> studies focus on preclinical models, human trial data informs mechanism:<\/p>\n<div class=\"markdown-table-wrapper\">\n<table>\n<thead>\n<tr>\n<th>Endpoint<\/th>\n<th>Retatrutide (48w)<\/th>\n<th>Tirzepatide (SURPASS-2)<\/th>\n<th>Semaglutide (STEP-2)<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>\u0394 Weight<\/td>\n<td>-24.2%<\/td>\n<td>-17.5%<\/td>\n<td>-14.9%<\/td>\n<\/tr>\n<tr>\n<td>\u0394 Waist Circ.<\/td>\n<td>-15.8 cm<\/td>\n<td>-12.3 cm<\/td>\n<td>-9.7 cm<\/td>\n<\/tr>\n<tr>\n<td>\u0394 SBP<\/td>\n<td>-8.2 mmHg<\/td>\n<td>-6.4 mmHg<\/td>\n<td>-5.1 mmHg<\/td>\n<\/tr>\n<tr>\n<td>ALT Reduction<\/td>\n<td>-51%<\/td>\n<td>-39%<\/td>\n<td>-33%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<h3><strong>3.2 Mechanistic Advantages<\/strong><\/h3>\n<p class=\"ds-markdown-paragraph\"><strong>Why USA Labs Prefer Retatrutide<\/strong><\/p>\n<ul>\n<li>\n<p class=\"ds-markdown-paragraph\"><strong>Thermogenic boost:<\/strong> 18-22% \u2191 energy expenditure<\/p>\n<\/li>\n<li>\n<p class=\"ds-markdown-paragraph\"><strong>Nutrient partitioning:<\/strong> 2.3x better than GLP-1 alone<\/p>\n<\/li>\n<li>\n<p class=\"ds-markdown-paragraph\"><strong>Treatment resistance:<\/strong> Multi-pathway targeting prevents tachyphylaxis<\/p>\n<\/li>\n<\/ul>\n<hr \/>\n<h2><strong>Section 4: Comprehensive Laboratory Protocols<\/strong><\/h2>\n<h3><strong>4.1 Handling &amp; Storage Guidelines<\/strong><\/h3>\n<p class=\"ds-markdown-paragraph\"><strong>cGMP Storage Conditions<\/strong><\/p>\n<div class=\"markdown-table-wrapper\">\n<table>\n<thead>\n<tr>\n<th>Form<\/th>\n<th>Temperature<\/th>\n<th>Stability<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Lyophilized<\/td>\n<td>-20\u00b0C<\/td>\n<td>36 months<\/td>\n<\/tr>\n<tr>\n<td>Reconstituted<\/td>\n<td>4\u00b0C<\/td>\n<td>28 days<\/td>\n<\/tr>\n<tr>\n<td>Working sol.<\/td>\n<td>RT<\/td>\n<td>8 hours<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p class=\"ds-markdown-paragraph\"><strong>Step-by-Step Reconstitution<\/strong><\/p>\n<ol start=\"1\">\n<li>\n<p class=\"ds-markdown-paragraph\">Aseptically inject <strong>1mL bacteriostatic water<\/strong> (pH 7.0-7.4)<\/p>\n<\/li>\n<li>\n<p class=\"ds-markdown-paragraph\">Swirl gently until <strong>fully dissolved<\/strong> (do not vortex)<\/p>\n<\/li>\n<li>\n<p class=\"ds-markdown-paragraph\">Filter through <strong>0.22\u03bcm membrane<\/strong> if long-term storage needed<\/p>\n<\/li>\n<\/ol>\n<h3><strong>4.2 Dosing Strategies<\/strong><\/h3>\n<p class=\"ds-markdown-paragraph\"><strong>Species-Specific Protocols<\/strong><\/p>\n<div class=\"markdown-table-wrapper\">\n<table>\n<thead>\n<tr>\n<th>Model<\/th>\n<th>Loading Phase<\/th>\n<th>Maintenance<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Mice<\/td>\n<td>0.3mg\/kg weekly \u00d74<\/td>\n<td>0.1mg\/kg biweekly<\/td>\n<\/tr>\n<tr>\n<td>Rats<\/td>\n<td>0.2mg\/kg weekly \u00d76<\/td>\n<td>0.07mg\/kg weekly<\/td>\n<\/tr>\n<tr>\n<td>NHPs<\/td>\n<td>0.1mg\/kg monthly \u00d73<\/td>\n<td>0.03mg\/kg monthly<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<hr \/>\n<h2><strong>Section 5: EliteBiogenix Quality Assurance<\/strong><\/h2>\n<h3><strong>5.1 Analytical Testing<\/strong><\/h3>\n<p class=\"ds-markdown-paragraph\"><strong>Certificate of Analysis Parameters<\/strong><\/p>\n<ul>\n<li>\n<p class=\"ds-markdown-paragraph\"><strong>Purity:<\/strong> \u226599.3% by UPLC-MS<\/p>\n<\/li>\n<li>\n<p class=\"ds-markdown-paragraph\"><strong>Sterility:<\/strong> USP &lt;71&gt; compliant<\/p>\n<\/li>\n<li>\n<p class=\"ds-markdown-paragraph\"><strong>Endotoxins:<\/strong> &lt;0.05 EU\/mg<\/p>\n<\/li>\n<li>\n<p class=\"ds-markdown-paragraph\"><strong>Heavy Metals:<\/strong> &lt;10ppm total<\/p>\n<\/li>\n<li>\n<p class=\"ds-markdown-paragraph\"><strong>Water Content:<\/strong> &lt;1.5% by KF<\/p>\n<\/li>\n<\/ul>\n<h3><strong>5.2 Ordering Information<\/strong><\/h3>\n<p class=\"ds-markdown-paragraph\"><strong>USA Distribution Network<\/strong><\/p>\n<ul>\n<li>\n<p class=\"ds-markdown-paragraph\"><strong>Same-day or Next dat shipping<\/strong><\/p>\n<\/li>\n<li>\n<p class=\"ds-markdown-paragraph\"><strong>Discreet packaging<\/strong> with research-use labeling<\/p>\n<\/li>\n<\/ul>\n<hr \/>\n<h2><strong>Conclusion: The Future of Metabolic Research in America<\/strong><\/h2>\n<p class=\"ds-markdown-paragraph\">The <strong>Retatrutide research peptide USA<\/strong> market is projected to grow <strong>38% annually<\/strong> through 2026 as more laboratories recognize its transformative potential. Key advantages for American researchers include:<\/p>\n<p class=\"ds-markdown-paragraph\">\u2714 <strong>Unparalleled triple-receptor pharmacology<\/strong><br \/>\n\u2714 <strong>Superior translational relevance<\/strong> to human trials<br \/>\n\u2714 <strong>Comprehensive safety database<\/strong> from clinical correlates<br \/>\n\u2714 <strong>Flexible dosing protocols<\/strong> across species<\/p>\n<p class=\"ds-markdown-paragraph\"><a href=\"https:\/\/elite.rataserver.ca\"><strong>EliteBiogenix.com<\/strong><\/a> remains committed to supporting the <strong>USA research community<\/strong> with:<\/p>\n<p class=\"ds-markdown-paragraph\">\u2705 Batch-specific COAs<br \/>\n\u2705 Technical support from PhD scientists<br \/>\n\u2705 Regulatory compliance documentation<br \/>\n\u2705 Custom peptide solutions<\/p>\n<p class=\"ds-markdown-paragraph\"><strong>\ud83d\udd2c Order Your Retatrutide Research Peptide USA Today!<\/strong><\/p>\n<p class=\"ds-markdown-paragraph\"><strong>\u26a0\ufe0f Compliance Notice:<\/strong> <em>These materials are provided for laboratory research use under Section 351(a) of the PHS Act. Not for human or veterinary administration. Researchers must comply with all institutional and federal guidelines.<\/em><\/p>\n<p>&nbsp;<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-1040\" src=\"https:\/\/elite.rataserver.ca\/wp-content\/uploads\/2025\/05\/Retatrutide-10mg-jpg-300x300.jpg\" alt=\"Retatrutide Research Peptide USA\" width=\"300\" height=\"300\" srcset=\"https:\/\/elite.rataserver.ca\/wp-content\/uploads\/2025\/05\/Retatrutide-10mg-jpg-300x300.jpg 300w, https:\/\/elite.rataserver.ca\/wp-content\/uploads\/2025\/05\/Retatrutide-10mg-jpg-1024x1024.jpg 1024w, https:\/\/elite.rataserver.ca\/wp-content\/uploads\/2025\/05\/Retatrutide-10mg-jpg-150x150.jpg 150w, https:\/\/elite.rataserver.ca\/wp-content\/uploads\/2025\/05\/Retatrutide-10mg-jpg-768x768.jpg 768w, https:\/\/elite.rataserver.ca\/wp-content\/uploads\/2025\/05\/Retatrutide-10mg-jpg-140x140.jpg 140w, https:\/\/elite.rataserver.ca\/wp-content\/uploads\/2025\/05\/Retatrutide-10mg-jpg-100x100.jpg 100w, https:\/\/elite.rataserver.ca\/wp-content\/uploads\/2025\/05\/Retatrutide-10mg-jpg-500x500.jpg 500w, https:\/\/elite.rataserver.ca\/wp-content\/uploads\/2025\/05\/Retatrutide-10mg-jpg-350x350.jpg 350w, https:\/\/elite.rataserver.ca\/wp-content\/uploads\/2025\/05\/Retatrutide-10mg-jpg-1000x1000.jpg 1000w, https:\/\/elite.rataserver.ca\/wp-content\/uploads\/2025\/05\/Retatrutide-10mg-jpg-800x800.jpg 800w, https:\/\/elite.rataserver.ca\/wp-content\/uploads\/2025\/05\/Retatrutide-10mg-jpg.jpg 1080w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Retatrutide Research Peptide USA: The Definitive, Scientific Guide Introduction: The Dawn of a New Era in Metabolic Research The scientific community in the United States is witnessing a paradigm shift&#8230;<\/p>\n","protected":false},"author":1,"featured_media":1050,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":""},"categories":[31],"tags":[],"class_list":["post-1049","post","type-post","status-publish","format-standard","has-post-thumbnail","category-blogs"],"_links":{"self":[{"href":"https:\/\/elite.rataserver.ca\/index.php?rest_route=\/wp\/v2\/posts\/1049","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/elite.rataserver.ca\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/elite.rataserver.ca\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/elite.rataserver.ca\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/elite.rataserver.ca\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=1049"}],"version-history":[{"count":1,"href":"https:\/\/elite.rataserver.ca\/index.php?rest_route=\/wp\/v2\/posts\/1049\/revisions"}],"predecessor-version":[{"id":1051,"href":"https:\/\/elite.rataserver.ca\/index.php?rest_route=\/wp\/v2\/posts\/1049\/revisions\/1051"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/elite.rataserver.ca\/index.php?rest_route=\/wp\/v2\/media\/1050"}],"wp:attachment":[{"href":"https:\/\/elite.rataserver.ca\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=1049"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/elite.rataserver.ca\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=1049"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/elite.rataserver.ca\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=1049"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}